Trials / Completed
CompletedNCT02124746
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Sierra Oncology LLC - a GSK company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.
Conditions
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis
- Polycythemia Vera
- Essential Thrombocythemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Momelotinib | Momelotinib tablets administered orally once daily |
Timeline
- Start date
- 2014-04-30
- Primary completion
- 2018-12-06
- Completion
- 2018-12-06
- First posted
- 2014-04-28
- Last updated
- 2023-06-18
- Results posted
- 2021-02-05
Locations
22 sites across 5 countries: United States, Australia, Canada, France, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02124746. Inclusion in this directory is not an endorsement.